Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliclazide MR add-on in type 2 diabetes inadequately controlled with dapagliflozin ± metformin
2024-511408-18-00Phase 3Completed
- Sponsor
- Servier
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Gliclazide MR + dapagliflozin ± metformin with Placebo + dapagliflozin ± metformin (2 arms). Primary endpoint: Change from baseline to week 24 in HbA1c. Started Jun 2024; status: completed.
02
Drugs
gliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-511408-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511408-18-00.